BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trigo-vicente C, Gimeno-ballester V, García-lópez S, López-del Val A. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. Int J Clin Pharm 2018;40:1411-9. [DOI: 10.1007/s11096-018-0743-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Pelletier JPR, Mukhtar F. Passive Monoclonal and Polyclonal Antibody Therapies. Immunologic Concepts in Transfusion Medicine. Elsevier; 2020. pp. 251-348. [DOI: 10.1016/b978-0-323-67509-3.00016-0] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ferrante M, Sabino J. Efficacy of JAK inhibitors in Ulcerative Colitis. J Crohns Colitis 2020;14:S737-45. [PMID: 31879750 DOI: 10.1093/ecco-jcc/jjz202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol 2019;12:1756284819848631. [PMID: 31205486 DOI: 10.1177/1756284819848631] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
4 Sakurai N, Shibata T, Nakamura M, Takano H, Hayashi T, Ota M, Nomura-Horita T, Hayashi R, Shimasaki T, Ostuka T, Tahara T, Arisawa T. Influence of MIF polymorphisms on CpG island hyper-methylation of CDKN2A in the patients with ulcerative colitis. BMC Med Genet 2020;21:201. [PMID: 33046033 DOI: 10.1186/s12881-020-01140-9] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Trigo-Vicente C, Gimeno-Ballester V, López-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. Eur J Hosp Pharm 2020;27:355-60. [PMID: 33097619 DOI: 10.1136/ejhpharm-2018-001833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Panés J, Gisbert JP. Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. Gastroenterología y Hepatología 2019;42:403-12. [DOI: 10.1016/j.gastrohep.2019.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:711-22. [PMID: 33599181 DOI: 10.1080/17474124.2021.1880319] [Reference Citation Analysis]
8 Patel H, Latremouille-viau D, Burne R, Shi S, Adsul S. Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019;1:otz022. [DOI: 10.1093/crocol/otz022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
9 Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol 2019;6:e000302. [PMID: 31413856 DOI: 10.1136/bmjgast-2019-000302] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
10 Fortuny Bauzá M, Cañete Pizarro F, Calm Salvans A, Calafat Sard M, Domènech Morral E. Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab. Gastroenterol Hepatol 2021:S0210-5705(21)00188-6. [PMID: 34118322 DOI: 10.1016/j.gastrohep.2021.05.005] [Reference Citation Analysis]
11 Benamu E. Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infect Dis Clin North Am 2020;34:271-310. [PMID: 32444011 DOI: 10.1016/j.idc.2020.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Reference Citation Analysis]
13 Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta‐analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. Clinical Pharmacy Therapeu. [DOI: 10.1111/jcpt.13622] [Reference Citation Analysis]
14 Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United European Gastroenterol J 2019;7:1285-303. [PMID: 31839954 DOI: 10.1177/2050640619883566] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
15 López-Sanromán A, Esplugues JV, Domènech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol 2021;44:39-48. [PMID: 32829958 DOI: 10.1016/j.gastrohep.2020.04.012] [Reference Citation Analysis]
16 Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. Drug Des Devel Ther 2019;13:4091-105. [PMID: 31819376 DOI: 10.2147/DDDT.S182891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]